Apolipoprotein C-II (ApoC2)

A 9-kDa protein component of VERY-LOW-DENSITY LIPOPROTEINS. It contains a cofactor for LIPOPROTEIN LIPASE and activates several triacylglycerol lipases. The association of Apo C-II with plasma CHYLOMICRONS; VLDL, and HIGH-DENSITY LIPOPROTEINS is reversible and changes rapidly as a function of triglyceride metabolism. Clinically, Apo C-II deficiency is similar to lipoprotein lipase deficiency (HYPERLIPOPROTEINEMIA TYPE I) and is therefore called hyperlipoproteinemia type IB.

Also Known As:

Networked: 148 relevant articles (2 outcomes, 16 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Howlett, Geoffrey J: 4 articles (11/2011 - 03/2004)
2.	Griffin, Michael D W: 3 articles (11/2011 - 11/2008)
3.	Hegele, Robert A: 2 articles (06/2015 - 07/2011)
4.	Jin, Rong: 2 articles (01/2015 - 01/2014)
5.	Huang, Zhi-Ming: 2 articles (01/2015 - 01/2014)
6.	Xie, Sai-Li: 2 articles (01/2015 - 01/2014)
7.	Chen, Tan-Zhou: 2 articles (01/2015 - 01/2014)
8.	Ishibashi, Shun: 2 articles (01/2013 - 01/2012)
9.	Gotoda, Takanari: 2 articles (01/2013 - 01/2012)
10.	Hung, Andrew: 2 articles (02/2011 - 11/2008)

Related Diseases

1.	Hypertriglyceridemia 08/01/2015 - "Taken together, our data suggest that the apoc2 mutant zebrafish is a robust and versatile animal model to study hypertriglyceridemia and the mechanisms involved in the pathogenesis of associated human diseases. " 06/01/1996 - "To localize transcriptional active cis elements and to study the effect of a single base transition at -86 derived from a patient (PS) with an inherited severe form of hypertriglyceridemia a reporter gene transfection assay with apo C-II promoter fragments was performed. " 08/01/2015 - "The hypertriglyceridemia in apoc2 mutants is rescued by injection of plasma from wild-type zebrafish or by injection of a human APOC2 mimetic peptide. " 08/01/2015 - "To develop a genetic model of hypertriglyceridemia, we generated an apoc2 mutant zebrafish characterized by the loss of Apoc2 function. " 05/01/2014 - "In vitro analysis confirmed that the autoantibody disrupted the interaction between apo C-II and lipid substrate, suggesting the etiological role of anti-apo C-II antibody in severe hypertriglyceridemia in this patient."
2.	Sepsis (Septicemia) 08/01/2010 - "The ApoSAA score computed from plasma apoC2 and SAA concentrations was effective in identifying sepsis/NEC cases in the case-control and cohort studies. " 01/01/2010 - "A recent study by Ng et al. identified two novel biomarkers for late-onset neonatal sepsis: the des-arginine variant of serum amyloid A and apolipoprotein C-II. These markers may be of value in the identification of neonates with bacteremia or fungemia."
3.	Fatty Liver 07/01/2003 - "The unique inborn hypertriglyceridemia seen in FLS (fatty liver Shionogi) mice was relieved by the administration of purified apolipoprotein (apo) C-II. Lipoprotein lipase (LPL) and its cofactor, apoC-II, play a pivotal role in VLDL metabolism. "
4.	Atherosclerosis 01/01/1988 - "Apart from a single example of an APO C-II 2-1 phenotype in plasma samples from 187 whites, which was electrophoretically identical to the 2-1 phenotype observed in blacks, it appears that APO C-II*2 is a unique black marker of potential importance in anthropogenetic and atherosclerosis studies." 05/01/2011 - "Apolipoprotein CII (ApoCII) and its negative regulator, apolipoprotein CIII (ApoCIII), have recently been described as atherogenesis biomarkers in models of cardiovascular disease. " 02/01/2015 - "The levels of ApoB, ApoC2,ApoC3,and ApoE and ApoB/ApoA1 ratio were significantly higher in the atherosclerosis group than in the control group (all P<0.01), whereas the ApoA1,ApoA2, and lipoprotein a levels showed no such significant difference (all P>0.05). " 05/15/2008 - "In this study, we show that mature human macrophages differentiated in the presence of IL-4, and dexamethasone (M2(IL-4/GC)) but not M2(IL-4) responds to TGF-beta1 which induced a gene expression program comprising 111 genes including transcriptional/signaling regulators (ID3 and RGS1), immune modulators (ALOX5AP and IL-17 receptor B) and atherosclerosis-related genes (ALOX5AP, ORL1, APOC1, APOC2, and APOE). " 01/01/2015 - "Levels of fundus atherosclerosis (AS) (P < 0.001), age (P < 0.001), serum biomarkers peroxidase (POD) (P = 0.026) and interleukin-6 (IL-6) (P = 0.001), serum levels of high-density lipoprotein cholesterol (HDL-C) (P < 0.001), apolipoprotein A2 (ApoA2) (P = 0.001), and ApoC2 (P = 0.005) showed significant differences. "
5.	Coronary Disease (Coronary Heart Disease) 07/01/2002 - "Several studies have suggested that an abnormal concentration of Apo C(II) may serve as a marker for deficient TRL metabolism, a possible cause of coronary heart disease (CHD). " 04/01/1992 - "Most importantly, the study revealed elevated apolipoprotein CII/CIII-B levels in coronary heart disease patients of both sexes compared with normal subjects. " 07/01/2002 - "Association between serum apolipoprotein C(II) concentration and coronary heart disease." 12/10/2001 - "To investigate the relationship between the polymorphism of apolipoprotein CII (apoCII) microsatellite DNA (TG) n (AG) m and coronary heart disease (CHD). " 12/10/2001 - "[Genetic polymorphism analysis of apolipoprotein CII microsatellite DNA (TG) n (AG) m in patients with coronary heart disease]."

Related Drugs and Biologics

1.	Apolipoproteins
2.	Lipoprotein Lipase (Diacylglycerol Lipase)
3.	Apolipoproteins C (ApoC)
4.	Apolipoproteins E (ApoE)
5.	Lipoproteins (Lipoprotein)
6.	Apolipoprotein C-III
7.	Cholesterol
8.	HDL Cholesterol
9.	Lipase (Acid Lipase)
10.	Proteins (Proteins, Gene)

Related Therapies and Procedures

1.	Homologous Transplantation (Allograft)
2.	Renal Dialysis (Hemodialysis)
3.	Aftercare (After-Treatment)